Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26465918 | 1.00 | MEN1 (0.32) | MEN1KMT2ADDB1CRBNF13A1 | |
| SCHEMBL26467602 | 0.84 | PTPN1 (0.33) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL26467780 | 0.84 | PTPN1 (0.33) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL26465914 | 0.81 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL5201608 | 0.81 | MEN1 (0.33) | MEN1KMT2ADDB1CRBNF13A1 | |
| SCHEMBL5201612 | 0.81 | MEN1 (0.33) | MEN1KMT2ADDB1CRBNF13A1 | |
| SCHEMBL6796073 | 0.79 | PTPN1 (0.35) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL26466302 | 0.74 | ALDH1A1 (0.33) | F13A1TGM2TGM1 | |
| SCHEMBL21367151 | 0.73 | MEN1 (0.33) | MEN1KMT2ADDB1CRBNF13A1 | |
| SCHEMBL21367006 | 0.71 | PTPN1 (0.34) | MEN1KMT2AF13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | MEN1 2856/4885KMT2A 2770/4885DDB1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.